Which weight loss injections cause the fewest side effects?

Step 1: Start with what both injections have in common

Mounjaro and Wegovy are both once-weekly subcutaneous injections that slow gastric emptying and reduce appetite through gut-hormone pathways. Because they share that mechanism, they share a broadly similar side-effect profile. Nausea tends to be the most frequently reported effect, followed by vomiting, diarrhoea, constipation, indigestion and burping. Fatigue, headache and injection-site reactions (mild redness or itching at the site) are also reported with both, though less often.

These effects are usually most noticeable in the first days after starting or after each dose step-up, and they commonly settle within a week or two as the body adjusts. Keeping a pen in the fridge door and injecting on the same evening each week can help you build a rhythm and notice whether symptoms cluster around a specific point in your cycle. That pattern is useful information to share with your prescriber. For a fuller picture of what to expect day to day, the side effects of weight loss injections page covers both medicines in more detail.

Step 2: Understand where the two medicines actually differ

Mounjaro activates two receptors (GIP and GLP-1) while Wegovy targets GLP-1 alone. In clinical trials, Mounjaro's dual action produced greater average weight loss: approximately 20–21% of body weight at the highest dose over 72 weeks in SURMOUNT-1, published in the New England Journal of Medicine. Wegovy at its standard 2.4mg maintenance dose produced around 15% over 68 weeks in the STEP 1 trial, also in the New England Journal of Medicine.

On tolerability, neither medicine has been shown in head-to-head data to produce meaningfully fewer side effects than the other at equivalent stages of titration. What does differ is the starting dose design. Mounjaro's titration ladder begins at 2.5mg, a dose whose primary purpose is allowing the body to adjust, not yet to drive significant weight loss. That deliberate ramp helps many people manage early nausea. Wegovy follows a similarly careful escalation from 0.25mg.

One practical difference is the contraception consideration: for tirzepatide specifically, women taking oral contraceptives are advised to add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because gastric slowing may reduce pill absorption. NHS guidance notes no equivalent evidence of this interaction for semaglutide. If you are weighing up which weight loss injection has less side effects for your individual circumstances, this is worth raising during your consultation.

Step 3: Recognise which side effects need prompt medical attention

Most gastrointestinal symptoms are uncomfortable rather than dangerous. The ones that warrant urgency are different in character. Severe, persistent abdominal pain that radiates toward the back (with or without vomiting) should not be waited out at home. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines; that update is worth reading if you are considering either injection.

Other situations to act on promptly: signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing), symptoms suggesting gallbladder problems (sharp pain under the right ribs after eating), and significant dehydration resulting from prolonged vomiting or diarrhoea. If you are taking insulin or sulfonylureas alongside a GLP-1 injection, your prescriber will already have discussed hypoglycaemia monitoring with you. The NHS tirzepatide patient information page sets out the full list of side effects and their urgency levels plainly.

You should also let your healthcare team know about any new or worsening low mood. This is documented in the Wegovy summary of product characteristics as a side effect to monitor, and it is something our prescribers ask about at every clinical review. If you have ever wondered do weight loss injections have side effects that go beyond the stomach, this is a good example of why the answer is broader than most people expect. If at any point after starting either injection something feels off and you can't reach your usual care team, contact us directly, aftercare is available seven days a week.

Step 4: What actually minimises side effects in practice

The titration design (starting low and increasing gradually under clinical supervision) is the most evidence-supported way to reduce the severity of early side effects. Trying to rush through dose increases typically makes symptoms worse, not better. Beyond the schedule itself, a few practical factors consistently come up in clinical practice: eating smaller portions of lower-fat food during the first weeks, staying well hydrated, avoiding lying flat immediately after eating, and not skipping doses then doubling up.

Which injection is better tolerated is genuinely individual. Some people do better on tirzepatide; some find Wegovy's single-pathway action easier on the gut early on. There is no universal answer, and that is precisely why a clinical conversation matters. If you want a closer look at weight loss injections with least side effects before that conversation, it is a useful starting point alongside the weight loss treatment overview, which explains how nume's prescribers approach this comparison. Our FAQs cover some of the most common questions we hear about managing side effects during titration, and our guide to which weight loss injection has the least side effects goes into further detail for anyone who wants to read more before deciding. Our clinical lead and the wider prescribing team discuss both medicines' profiles as a standard part of every consultation, including which, if either, fits your health picture. Speak to our prescribers to explore which option makes sense for you.